Placebo + DS-5565
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Herpetic Neuralgia
Conditions
Post-Herpetic Neuralgia
Trial Timeline
Jan 1, 2015 → May 25, 2017
NCT ID
NCT02318719About Placebo + DS-5565
Placebo + DS-5565 is a pre-clinical stage product being developed by Daiichi Sankyo for Post-Herpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02318719. Target conditions include Post-Herpetic Neuralgia.
What happened to similar drugs?
1 of 1 similar drugs in Post-Herpetic Neuralgia were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02318719 | Pre-clinical | Completed |
Competing Products
5 competing products in Post-Herpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| BMS-954561 + BMS-954561 + Placebo | Bristol Myers Squibb | Phase 2 | 35 |
| HSK16149，probenecid, cimetidine | Haisco Pharmaceutical Group | Phase 1 | 29 |